Cargando…
Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs
SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that cannot be treated with endocrine therapy and Her2-targeted therapy. Although its prevalence among newly diagnosed breast cancers is approximately 12.7%, it accounts for 40% of breast cancer-rela...
Autores principales: | Wu, Qitong, Siddharth, Sumit, Sharma, Dipali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345029/ https://www.ncbi.nlm.nih.gov/pubmed/34359598 http://dx.doi.org/10.3390/cancers13153697 |
Ejemplares similares
-
Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation
por: Zheng, Hongmei, et al.
Publicado: (2021) -
Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants
por: Siddharth, Sumit, et al.
Publicado: (2018) -
Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy
por: Wu, Qitong, et al.
Publicado: (2023) -
Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
por: Parveen, Sadiya, et al.
Publicado: (2021) -
Bioactive Compounds: Multi-Targeting Silver Bullets for Preventing and Treating Breast Cancer
por: Muniraj, Nethaji, et al.
Publicado: (2019)